S
ED, Portfolio Strategy and Strategic Planning, Global Human Health, Merck
MOST RECENT HIT: Global marketing of diabetes blockbuster Januvia
ROLE MODELS: William F. Buckley, Jr. ("strategic thinking, conservative, firm, a change agent")
Blair Gibson
Blair Gibson always wanted a career in pharma. He studied medicinal chemistry, and had his heart set on research until his mentor gave him a reality check. "He said, 'You'd be a disaster in the lab, but you have a very outgoing personality. Your route should be on the commercial side." Harsh—but good advice. Starting out in the field, Gibson gained a place on the team that brought first-in-class diabetes drug Januvia to market—widely viewed as one of the fastest, most successful launches in pharma history. His reward? A promotion in January to a newly created position that Gibson translates as optimizing Merck's promotional spend across all marketed and pipeline products, and all geographies. "Strategy around resource allocation and portfolio management is needed now more than ever," Gibson says. "And while the discipline is flying below the radar, when the work starts coming out in June or July, it will be a new process, a new framework, a new way of looking at our promotional spend"—estimated to be as high as $8 billion. That's a lot of chips to gamble with. For Gibson, it allows him to keep his eye on the big picture while giving his outgoing personality a chance to make a big impact.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.